Diagnos Inc V.ADK

Alternate Symbol(s): DGNOF

Healthcare Medical Devices

DIAGNOS Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for modifying and developing of applications, such as Computer Assisted Retina Analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. Its geographical areas include Canada, the United States, Saudi Arabia, Mexico, Costa Rica and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.

TSXV:ADK - Post by User

Diagnos Inc

Bullboard Posts

Comment by wasagastaron Jul 14, 2017 7:57pm

107 Views

Post# 26471776

RE:After Diabetic retinopathy, moving to another market???

Bencro, great info and doing retinopathy for cardiology is the holy grail. You highlited revenue expectations of 2.76 x revenue of 2016 as expectations for 2017. If they can land 40k tests a year from Mexico it would be huge. Revenue jumps significantly. 50k even better.

bencro wrote: Diabetes and cardiology are closely related in terms of health issues. This is a very well documented subject.

Examples:

The Cardiologist's Role In The Management Of Type 2 Diabetes - A Review

DIABETES, PRE-DIABETES AND CARDIOVASCULAR DISEASES DEVELOPED WITH THE EASD

In the last MD&A of May 2017, the company clearly stated that it expects to grow its revenues by 2.76x over the next 12 months.

So expect more news soon on expansion of market related applications, if this technology works fine in the diabetes markets.

Jan. 24, 2017:

DIAGNOS Successfully Completes a 2,000 Patient Pilot Project for the Mexican Social Security Institute

The pilot project helped demonstrate that a well-planned wellness program can have a positive impact on the diabetes epidemic. DIAGNOS' Artificial Intelligence tools (CARA) contributed at accurately identifying related diseases linked to diabetes in 98% of tests conducted.